trending Market Intelligence /marketintelligence/en/news-insights/trending/imunp6bfrnyerhswdchvma2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eisai's anticancer drug approved in Japan to treat liver cancer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Eisai's anticancer drug approved in Japan to treat liver cancer

Tokyo-based Eisai Co. Ltd. said its drug Lenvima was approved in Japan as a primary treatment for liver cancer that cannot be removed surgically.

This is the first time the drug has been approved as a first-line treatment of unresectable hepatocellular carcinoma in the world.

It also marks the first approval of the drug under Eisai's global collaboration with Merck & Co. Inc. to co-develop and co-commercialize the treatment, either on its own or in combination with Merck's blockbuster drug Keytruda.

Eisai will receive a development milestone payment from Merck as a result of the approval which was based on the results of a late-stage clinical trial that demonstrated Lenvima was just as effective as Bayer AG's Nexavar on the primary endpoint.

Eisai's treatment proved to be better than Bayer's drug in the secondary endpoints which measured how long a patient lived without the disease worsening and reduction in a subject's cancer.

Analysts expect Lenvima to be a real contender to Bayer's Nexavar which has enjoyed a decadelong monopoly in the liver cancer market.

Eisai is also seeking approval of the drug in the U.S., EU and China as a treatment of hepatocellular carcinoma.

Lenvima, generically known as lenvatinib mesylate, is a kinase inhibitor that blocks cancer growth.